Lyell Immunopharma
LYEL
99 hedge funds and large institutions have $278M invested in Lyell Immunopharma in 2023 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 30 increasing their positions, 23 reducing their positions, and 13 closing their positions.
62% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 13
30% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 23
8% more funds holding
Funds holding: 92 → 99 (+7)
0.02% more ownership
Funds ownership: 2.34% → 2.36% (+0.02%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
31% less capital invested
Capital invested by funds: $404M → $278M (-$126M)
75% less call options, than puts
Call options by funds: $2K | Put options by funds: $8K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$4.42M |
| 2 |
Millennium Management
New York
|
+$925K |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$780K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$725K |
| 5 |
Invesco
Atlanta,
Georgia
|
+$624K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$2.43M |
| 2 |
State Street
Boston,
Massachusetts
|
-$2.22M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.78M |
| 4 |
Goldman Sachs
New York
|
-$1.76M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$1.22M |
LYEL Hedge Fund Activity: Q1 2023 in Review
99 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q1 2023, worth a combined $278M — down 31% from $404M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new LYEL positions and 13 closed out — a net gain of 8 holders — while 30 added to existing stakes and 23 trimmed.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $4.42M. The largest seller was Artal Group, exiting entirely with an estimated $2.43M sold.
- 99 institutional investors held Lyell Immunopharma (LYEL) as of Q1 2023, up from 92 in Q4 2022.
- Funds reported $278M of Lyell Immunopharma stock for Q1 2023, down 31% quarter-over-quarter.
- 21 funds opened new Lyell Immunopharma positions in Q1 2023 and 13 closed out, a net change of +8 holders.
- The largest Lyell Immunopharma buyer in Q1 2023 was Jacobs Levy Equity Management, an estimated $4.42M added.
- The largest Lyell Immunopharma seller in Q1 2023 was Artal Group, an estimated $2.43M sold.
Based on aggregated 13F filings for Q1 2023.